On Sept. 8, 2020, DiaSorin Molecular announced that it had received FDA Clearance for its Simplexaﾙ Flu A/B & RSV Direct Gen II kit. The
Simplexa Flu A/B & RSV Direct Gen II assay provides flexibility in workflow management for the flu season as the assay can be run alone or alongside
the Simplexa COVID-19 Direct kit, allowing for differential diagnosis of SARS-CoV-2, influenza A (Flu A), influenza B (Flu B), and respiratory syncytial virus (RSV).